Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Allogene's new CEO Zachary Roberts outlined a strategic refocus on leveraging the intrinsic advantages of allogeneic (off-the-shelf) CAR-T — ready availability, consistent product quality, and ability ...

Allora's price outlook hinges on adoption versus token unlocks in a volatile AI-crypto niche. Adoption vs. Unlocks – Only ~20% of the 1B ALLO supply circulates, with major backer unlocks extending to ...

The chatter on ALLO is a mix of cautious optimism and technical skepticism. Here’s what’s trending: Traders are watching key support and resistance levels after a volatile breakout, wary of a bull ...

Ready to watch 'Allo 'Allo!? This 1984 Comedy/War & Politics series is available to watch right now. It's currently streaming on Amazon Prime Video, Peacock Premium, BritBox, Peacock Premium Plus, ...

Profound Medical Corp. is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue ...

Allogene Therapeutics presented positive Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy, for renal cell carcinoma (RCC) at the 2025 ASCO Annual Meeting. The study showed ...

Prof G Markets is your daily briefing on the news moving markets — from earnings and geopolitics, to Big Tech and AI. Hosted by Scott Galloway and Ed Elson, we cut through the noise with no-BS ...